Author

M. A. Caligiuri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

J. Yu· 3 shared J. Yan· 2 shared J. Zhang· 2 shared S. Ma· 2 shared W. Dong· 2 shared A. L. Engelbrektson· 1 shared A. S. Boyle· 1 shared B. M. Barker· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

J. Yu

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression

M. A. Caligiuri, J. Yu, Y. Sun, W. Dong, L. Tian, Y. Rao, C. Qin, S. A. Jaramillo, E. W. Settles, S. Ma, J. Zhang, K. Yu, B. Xu, J. Yan, R. Ma, , P. Feng

This paper develops an oncolytic viral vector-based vaccine that prevents COVID-19 and treats tumor progression in preclinical models.

bioRxiv · Jun 7, 2021 · PreprintMicrobiology

The RNA m6A reader YTHDF2 controls NK cell anti-tumor and anti-viral immunity

S. Ma, J. Yan, T. Barr, J. Zhang, Z. Chen, L.-S. Wang, J. C. Sun, J. Chen, M. A. Caligiuri, J. Yu

This study shows YTHDF2, an m6A reader, enhances NK cell anti-tumor and anti-viral responses by regulating homeostasis, maturation, and effector function through STAT5 feedback and Tardbp interactions.

bioRxiv · Apr 26, 2021Immunology

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoV

J. T. Ladner, S. N. Henson, A. S. Boyle, A. L. Engelbrektson, Z. W. Fink, F. Rahee, J. D'ambrozio, K. E. Schaecher, M. Stone, W. Dong, S. Dadwal, J. Yu, M. A. Caligiuri, P. Cieplak, M. Bjoras, , J. A. Altin

This study uses PepSeq to map SARS-CoV-2 antibody epitopes and identifies cross-reactivity with hCoV-OC43.

bioRxiv · Jul 27, 2020Immunology